EUVIMEDEUVIMED entdecken
Crossref

Cryptotanshinone inhibits osteoclast differentiation by targeting LCP1 to suppress diabetic osteoporosis

Mingming Li, Yixin Zhang, Ya Fang, Siyu Chen

International Immunopharmacology · 2026-02 · 170 · 116115

DOI: 10.1016/j.intimp.2025.116115 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2026-02. Verfasst von Mingming Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou 215000, China. Hauptthemen laut MEDLINE: Phenanthrenes, Osteoclasts, Osteoporosis, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As a frequent complication of diabetes, diabetic osteoporosis (DOP) represents a growing clinical and public health challenge. The increased osteoclastogenesis in diabetic pathological states results in bone resorption and bone loss and the exacerbation of osteoporosis. Cryptotanshinone, a fat-soluble diterpenoid anthraquinone compound extracted from Salvia. miltiorrhiza Bge, has been demonstrated efficacy in the treatment of a variety of diseases. In this study, we present evidence that cryptotanshinone inhibits RANKL-induced osteoclast differentiation in a concentration-dependent manner in vitro. Furthermore, cryptotanshinone suppresses diabetic osteoporosis by inhibiting osteoclastogenesis in vivo. Mechanistically, cryptotanshinone binds to lymphocyte cytosolic protein 1 (LCP1) so that suppressing osteoclast fusion to reduce bone resorption. Collectively, these findings suggest that cryptotanshinone suppresses osteoclast differentiation and bone loss of DOP by targeting LCP1. Consequently, cryptotanshinone may represent a promising therapeutic agent for diabetic osteoporosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenanthrenesOsteoclastsOsteoporosisDiabetes Mellitus, ExperimentalDiabetes ComplicationsAnimalsCell DifferentiationMiceHumansMice, Inbred C57BLOsteogenesisMaleRANK LigandRAW 264.7 CellsSalvia miltiorrhiza

Stichwörter der Autor:innen

CryptotanshinoneDiabetic osteoporosisLCP1Osteoclast differentiation

Substanzen

cryptotanshinonePhenanthrenesRANK Ligand

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou 215000, China.
  • Department of Basic Medicine, Dali University, Dali, Yunnan 671000, China.
  • Department of Endocrinology and Metabolism, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou 215000, China. Electronic address: fang_ya1993@163.com.
  • Department of Endocrinology and Metabolism, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou 215000, China. Electronic address: justin_yesterday@outlook.com.

Förderung

  • Natural Science Foundation of Jiangsu Province
  • National Natural Science Foundation of China

Zitieren

APA

Li, M., Zhang, Y., Fang, Y., & Chen, S. (2026). Cryptotanshinone inhibits osteoclast differentiation by targeting LCP1 to suppress diabetic osteoporosis. International Immunopharmacology, 170, 116115. https://doi.org/10.1016/j.intimp.2025.116115

Vancouver

Li M, Zhang Y, Fang Y, Chen S. Cryptotanshinone inhibits osteoclast differentiation by targeting LCP1 to suppress diabetic osteoporosis. International Immunopharmacology. 2026;170:116115. doi:10.1016/j.intimp.2025.116115

BibTeX
@article{Li2026,
  author = {Li, Mingming and Zhang, Yixin and Fang, Ya and Chen, Siyu},
  title = {Cryptotanshinone inhibits osteoclast differentiation by targeting LCP1 to suppress diabetic osteoporosis},
  journal = {International Immunopharmacology},
  year = {2026},
  volume = {170},
  pages = {116115},
  doi = {10.1016/j.intimp.2025.116115}
}
Kostenlos starten →